https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513=
9PTmAm2ORJ-2Fb7C-2B6elFAkTlNf9IRjfBprWAH-2BoSMH0AUOFDMRvrkbihvX-2F5t0iQMiPP=
5ZY2iYlZidSB36hw405CYeyNJ2tBe4rk3lpDOiVp_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVW=
u7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic-2FUwvA-2BfPsk4gNr-2BW6M70OIHMB7vQEQ19e=
cNE7nFy8buOLD3011XKEBm5XlxgihIWov8LLIWj4b4iR9qSmoqQ1bPTPP-2BLiQmRDbGKXNv5dB=
oNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp3-2BXiwyjx1RnsuG7lSji9VHDM-2B8y8UJZ6iRk=
GQfiaGcWLUfTToy0HRqVg8dPD5lC-2FVAbGUuLm7utbZi-2BDbdga1L3EuV-2FqViUJC4iNbCjZ=
EmMAK8NPjgFBmadTzFT08dmfrE8saupz9JrUVMwTLL-2Bq-2BY-2BVQ-3D
** BIMZELX^=C2=AE (bimekizumab) Receives Approval in Japan for the Treatmen=
t of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Anky=
losing Spondylitis
------------------------------------------------------------
=C2=B7 Bimekizumab is the first IL-17A and IL-17F inhibitor to receive regu=
latory approval in Japan for the treatment of psoriatic arthritis (PsA), no=
n-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondyliti=
s (AS) in adult patients
=C2=B7 The extended approval for bimekizumab in Japan follows its first app=
roval in January 2022 for plaque psoriasis, generalized pustular psoriasis,=
and psoriatic erythroderma=C2=A0
=C2=B7 This represents the third approval by regulatory authorities around =
the world for bimekizumab in PsA, nr-axSpA and AS=C2=A0
Brussels (Belgium), 27th December 2023 =E2=80=93 07:00 (CET) =E2=80=93 UCB,=
a global biopharmaceutical company, today announced that the Japanese Mini=
stry of Health, Labour and Welfare (MHLW) has approved BIMZELX^=C2=AE (bime=
kizumab) for the treatment of adults with psoriatic arthritis (PsA), non-ra=
diographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) who are not suf=
ficiently responding to existing treatments.^1 The new indications for bime=
kizumab in Japan follow its first approval in January 2022 for the treatmen=
t of plaque psoriasis, generalized pustular psoriasis, and psoriatic erythr=
oderma.^1 Bimekizumab is the first IL-17A and IL-17F inhibitor to receive r=
egulatory approval in Japan for the treatment of PsA, nr-axSpA and AS in ad=
ult patients. This milestone also represents the third approval for bimekiz=
umab in PsA, nr-axSpA and AS in 2023, following approval for these addition=
al indications in countries of the European Union/European Economic Area an=
d in Great Britain in June and August 2023, respectively.^2,3
=E2=80=9CWe are excited to bring bimekizumab as a new treatment option for =
people in Japan living with psoriatic arthritis and those living with axial=
spondyloarthritis. The extended approval for bimekizumab in Japan beyond t=
he psoriasis indications expands the reach of the first dual IL-17A and IL-=
17F inhibitor and marks another step forward in our ambition to transform l=
ives,=E2=80=9D said Emmanuel Caeymaex, Executive Vice President, Immunology=
Solutions and Head of U.S., UCB.
Bimekizumab was approved in Japan for the treatment of adult patients with =
PsA. The approval is based on data from the Phase 3 BE COMPLETE and BE OPTI=
MAL studies published as back-to-back manuscripts in The Lancet.^4,5=C2=A0B=
imekizumab was also approved in Japan for the treatment of adult patients w=
ith ankylosing spondylitis and non-radiographic axial spondyloarthritis. Th=
e approval is based on data from the Phase 3 BE MOBILE 1 and BE MOBILE 2 st=
udies, published in Annals of the Rheumatic Diseases.^6 The safety profile =
of bimekizumab in all four studies was consistent with safety data seen in =
previous studies with no new observed safety signals.^4,5,6
UCB is committed to bringing bimekizumab to patients with PsA and axSpA wor=
ldwide. Regulatory reviews are underway in other countries including Austra=
lia, Canada, Switzerland and China (axSpA only).
Notes to editors:
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a serious, highly heterogeneous, chronic, syst=
emic inflammatory condition affecting both the joints and skin, with a prev=
alence of 0.02 percent to 0.25 percent of the population, and 6 percent to =
41 percent of patients with psoriasis. =C2=A0Symptoms include joint pain an=
d stiffness, skin plaques, swollen toes and fingers (dactylitis) and inflam=
mation of the sites where tendons or ligaments insert into the bone (enthes=
itis).^8
About Axial Spondyloarthritis
Axial spondyloarthritis (axSpA), which includes both non-radiographic axSpA=
(nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axS=
pA (r-axSpA), is a chronic, immune-mediated, inflammatory disease.^9 nr-axS=
pA is defined clinically by the absence of definitive x-ray evidence of str=
uctural damage to the sacroiliac joints.^9 axSpA is a painful condition tha=
t primarily affects the spine and the joints linking the pelvis and lower s=
pine (sacroiliac joints).^9 The leading symptom of axSpA in a majority of p=
atients is inflammatory back pain that improves with exercise but not with =
rest.^9 Other common clinical features frequently include anterior uveitis,=
enthesitis, peripheral arthritis, psoriasis, inflammatory bowel disease an=
d dactylitis.^9 The overall prevalence of axSpA is 0.3 percent to 1.3 perce=
nt of adults.^10,11=C2=A0 Approximately half of all patients with axSpA are=
patients with nr-axSpA.^9 axSpA onset usually occurs before the age of 45.=
9 Approximately 10 to 40 percent of patients with nr-axSpA progress to AS o=
ver 2 to 10 years.^9
About BE OPTIMAL and BE COMPLETE
The safety and efficacy of bimekizumab (160 mg every four weeks) were evalu=
ated in adult patients with active psoriatic arthritis (PsA) in two phase 3=
multicentre, randomized, double-blind, placebo-controlled studies (BE OPTI=
MAL and BE COMPLETE).^4,5 The BE OPTIMAL study evaluated 852 patients not p=
reviously exposed to any biologic disease-modifying anti-rheumatic drug (bD=
MARD-na=C3=AFve) for the treatment of active psoriatic arthritis.^4 The BE =
COMPLETE study evaluated 400 patients with an inadequate response or intole=
rance to treatment with one or two tumour necrosis factor-alpha inhibitors =
(TNFi-IR) for active psoriatic arthritis.^5 Detailed findings from the BE O=
PTIMAL and BE COMPLETE studies are published in The Lancet.^4,5
About BE MOBILE 1 and BE MOBILE 2=C2=A0
The efficacy and safety of bimekizumab (160 mg every four weeks) were evalu=
ated in 586 adult patients with active axial spondyloarthritis (axSpA) in t=
wo phase 3 multicenter, randomized, double-blind, placebo-controlled studie=
s, one in non-radiographic axSpA (nr-axSpA; BE MOBILE 1) and one in ankylos=
ing spondylitis (AS; BE MOBILE 2), also known as radiographic axSpA.^6 The =
BE MOBILE 1 and BE MOBILE 2 studies evaluated 254 and 332 patients, respect=
ively.^6 Detailed findings from the BE MOBILE 1 and BE MOBILE 2 studies are=
published in the Annals of the Rheumatic Diseases.^6
About bimekizumab =E2=96=BC=C2=A0in the EU
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to sel=
ectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)=
, two key cytokines driving inflammatory processes. =C2=A0The therapeutic i=
ndications in the European Union are:
=C2=B7 Plaque psoriasis: Bimekizumab is indicated for the treatment of mode=
rate to severe plaque psoriasis in adults who are candidates for systemic t=
herapy.^2=C2=A0
=C2=B7 Psoriatic arthritis: Bimekizumab, alone or in combination with metho=
trexate, is indicated for the treatment of active psoriatic arthritis in ad=
ults who have had an inadequate response or who have been intolerant to one=
or more disease-modifying antirheumatic drugs (DMARDs).^2
=C2=B7 Axial Spondyloarthritis: Bimekizumab is indicated for the treatment =
of adults with active non-radiographic axial spondyloarthritis with objecti=
ve signs of inflammation as indicated by elevated C-reactive protein (CRP) =
and/or magnetic resonance imaging (MRI) who have responded inadequately or =
are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs) and for th=
e treatment of adults with active ankylosing spondylitis who have responded=
inadequately or are intolerant to conventional therapy.^2
BIMZELX^=C2=AE =E2=96=BC (bimekizumab) EU/EEA* Important Safety Information=
^2
The most frequently reported adverse reactions with bimekizumab were upper =
respiratory tract infections (14.5%, 14.6%, 16.3% in plaque psoriasis (PSO)=
, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), respective=
ly) and oral candidiasis (7.3%, 2.3%, 3.7% in PSO, PsA and axSpA, respectiv=
ely). Common adverse reactions (=E2=89=A51/100 to <1/10) were oral candidia=
sis, tinea infections, ear infections, Herpes simplex infections, oropharyn=
geal candidiasis, gastroenteritis, folliculitis, headache, rash, dermatitis=
and eczema, acne, injection site reactions, fatigue. Elderly may be more l=
ikely to experience certain adverse reactions such as oral candidiasis, der=
matitis and eczema when using bimekizumab.
Bimekizumab is contraindicated in patients with hypersensitivity to the act=
ive substance or any of the excipients and in patients with clinically impo=
rtant active infections (e.g. active tuberculosis).
Bimekizumab may increase the risk of infections. Treatment with bimekizumab=
must not be initiated in patients with any clinically important active inf=
ection. Patients treated with bimekizumab should be instructed to seek medi=
cal advice if signs or symptoms suggestive of an infection occur. If a pati=
ent develops an infection the patient should be carefully monitored. If the=
infection becomes serious or is not responding to standard therapy, treatm=
ent should be discontinued until the infection resolves. Prior to initiatin=
g treatment with bimekizumab, patients should be evaluated for tuberculosis=
(TB) infection. Bimekizumab should not be given in patients with active TB=
. Patients receiving bimekizumab should be monitored for signs and symptoms=
of active TB.
Cases of new or exacerbations of inflammatory bowel disease have been repor=
ted with bimekizumab. Bimekizumab is not recommended in patients with infla=
mmatory bowel disease. If a patient develops signs and symptoms of inflamma=
tory bowel disease or experiences an exacerbation of pre-existing inflammat=
ory bowel disease, bimekizumab should be discontinued and appropriate medic=
al management should be initiated.
Serious hypersensitivity reactions including anaphylactic reactions have be=
en observed with IL-17 inhibitors. If a serious hypersensitivity reaction o=
ccurs, administration of bimekizumab should be discontinued immediately and=
appropriate therapy initiated.
Live vaccines should not be given in patients treated with bimekizumab.
Please consult the Summary of Product Characteristics in relation to other =
side effects, full safety and prescribing information.
European SmPC date of revision: November 2023.=C2=A0
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdN3E=
U-2FWvZebf3RrOmE3Tk7MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH6uJI6dDXHRika=
HhL8HIZVsPc5Q6uIhYECs-2Fl2G-2Bmd0FHEEN1rJ7-2FbHVsMI0nMnjAQ-3D-3DLkbb_xDPID0=
vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic-2FUwvA-2Bf=
Psk4gNr-2BW6M70OIHMB7vQEQ19ecNE7nFy8buOLD3011XKEBm5XlxgihIWov8LLIWj4b4iR9qS=
moqQ1bPTPP-2BLiQmRDbGKXNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp3-2BXtxj-2F=
m-2FdEPSvzqwQnXcUpjvg88uGC4No-2Fjp5EhvKrcZmsoqC6oWUthLaQr6j4FAM4RU5jwh1WLDR=
X73WxRUJW2CrNlKE6zShsAkXCy4-2FDLrrFxmDhNw6pag-2F2gvWR6FqihwaR-2FmnncEbboyP1=
Tb2TJg-3D
Last Accessed: December 2023
*EU/EEA: European Union/European Economic Area
=E2=96=BC=C2=A0 This medicinal product is subject to additional monitoring.=
This will allow quick identification of new safety information. Healthcare=
professionals are asked to report any suspected adverse reactions.
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
T +32.2.559.94.14=C2=A0
email antje.witte@ucb.com=C2=A0
Corporate Communications
Laurent Schots=C2=A0
T +32.2.559.92.64=C2=A0
email laurent.schots@ucb.com
Brand Communications
Eimear O=E2=80=99Brien
T +32.2.559.92.71
email eimear.obrien@ucb.com=C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,700 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: change=
s in general economic, business and competitive conditions, the inability t=
o obtain necessary regulatory approvals or to obtain them on acceptable ter=
ms or within expected timing, costs associated with research and developmen=
t, changes in the prospects for products in the pipeline or under developme=
nt by UCB, effects of future judicial decisions or governmental investigati=
ons, safety, quality, data integrity or manufacturing issues; potential or =
actual data security and data privacy breaches, or disruptions of our infor=
mation technology systems, product liability claims, challenges to patent p=
rotection for products or product candidates, competition from other produc=
ts including biosimilars, changes in laws or regulations, exchange rate flu=
ctuations, changes or uncertainties in tax laws or the administration of su=
ch laws, and hiring and retention of its employees. There is no guarantee t=
hat new product candidates will be discovered or identified in the pipeline=
, will progress to product approval or that new indications for existing pr=
oducts will be developed and approved. Movement from concept to commercial =
product is uncertain; preclinical results do not guarantee safety and effic=
acy of product candidates in humans. So far, the complexity of the human bo=
dy cannot be reproduced in computer models, cell culture systems or animal =
models. The length of the timing to complete clinical trials and to get reg=
ulatory approval for product marketing has varied in the past and UCB expec=
ts similar unpredictability going forward. Products or potential products, =
which are the subject of partnerships, joint ventures or licensing collabor=
ations may be subject to differences disputes between the partners or may p=
rove to be not as safe, effective or commercially successful as UCB may hav=
e believed at the start of such partnership. UCB=E2=80=99s efforts to acqui=
re other products or companies and to integrate the operations of such acqu=
ired companies may not be as successful as UCB may have believed at the mom=
ent of acquisition. Also, UCB or others could discover safety, side effects=
or manufacturing problems with its products and/or devices after they are =
marketed. The discovery of significant problems with a product similar to o=
ne of UCB=E2=80=99s products that implicate an entire class of products may=
have a material adverse effect on sales of the entire class of affected pr=
oducts. Moreover, sales may be impacted by international and domestic trend=
s toward managed care and health care cost containment, including pricing p=
ressure, political and public scrutiny, customer and prescriber patterns or=
practices, and the reimbursement policies imposed by third-party payers as=
well as legislation affecting biopharmaceutical pricing and reimbursement =
activities and outcomes. Finally, a breakdown, cyberattack or information s=
ecurity breach could compromise the confidentiality, integrity and availabi=
lity of UCB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release. UCB expressly disclaims any duty t=
o update any information contained in this press release, either to confirm=
the actual results or to report or reflect any change in its forward-looki=
ng statements with regard thereto or any change in events, conditions or ci=
rcumstances on which any such statement is based, unless such statement is =
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
References
1. Pharmaceuticals and Medical Devices Agency. Available at: https://u70611=
46.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUctH3QCMZpjn516dr7a=
ew1MQ1Dbor6FwplR6QeJQnQCT1B5flNbOSTYWv-2BCgN7j6zq4ysaDl9r8oZOxhR6rwtl-2FIvV=
s9PtZRmoagf4dEHcomWzmBEaFi1xrqmcx1ig5wdQ-3D-3DOfkP_xDPID0vOuylFAU8fv4e60wei=
4JxqEGBdVWu7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic-2FUwvA-2BfPsk4gNr-2BW6M70OIH=
MB7vQEQ19ecNE7nFy8buOLD3011XKEBm5XlxgihIWov8LLIWj4b4iR9qSmoqQ1bPTPP-2BLiQmR=
DbGKXNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp3-2BXrIID4gMtXQ0lEE3whpr-2BWv=
vvZEYyc-2Fol99DXX0s-2B-2FyfraSAn5Slt2F-2FmYUJy0NvaakoFkpNsn2-2F7p5VEc4UuM5l=
RFQumcHUYu6boGEtxlQNvfdPKS-2FptbSse3wsBTvCuSYuf2oBWuSA6qH6IOq1vcc-3D Last a=
ccessed: December 2023.
2. BIMZELX^=C2=AE (bimekizumab) EU SmPC. Available at: https://u7061146.ct.=
sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdN3EU-2FWvZebf3RrOmE3Tk7=
MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH6uJI6dDXHRikaHhL8HIZVsPc5Q6uIhYEC=
s-2Fl2G-2Bmd0FmcyR4Sx9QdcHWQECFWENWQ-3D-3DvYeV_xDPID0vOuylFAU8fv4e60wei4Jxq=
EGBdVWu7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic-2FUwvA-2BfPsk4gNr-2BW6M70OIHMB7v=
QEQ19ecNE7nFy8buOLD3011XKEBm5XlxgihIWov8LLIWj4b4iR9qSmoqQ1bPTPP-2BLiQmRDbGK=
XNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp3-2BXmn55ynFlPK-2F7XtxmqU4Q68lJrv=
KpyfLOip5GfTW3r26DtOlHR63OI2q0-2FqkhXrO1h9TbgNSYrGcYfKaju-2B763YzRFnaxXo4Sy=
aBj6G-2BQsqqkefFavUOPrqrx9-2BP-2BPuxUtztMVHCY9-2FM7vZRuBW4gyU-3D Last acces=
sed: December 2023.
3. BIMZELX^=C2=AE (bimekizumab) GB SmPC. Available at: https://u7061146.ct.=
sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUc8WVK0-2FE-2FQTozpsM-2Fg=
7fzcyxp0msekY8-2B21IQeRydaoznNdLNxUuN-2BK8OVc2e7jmYv7LWhy4TUt268AnTwYmJo-3D=
90Fy_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic=
-2FUwvA-2BfPsk4gNr-2BW6M70OIHMB7vQEQ19ecNE7nFy8buOLD3011XKEBm5XlxgihIWov8LL=
IWj4b4iR9qSmoqQ1bPTPP-2BLiQmRDbGKXNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp=
3-2BXmNgcOmbSr4lYDHgoMaabcttTDuVMq3q9LHti7MdyFpbKNSQ9fI8wy24D5RN8d8aRi-2Bli=
ybq4OuuRO0fshmf6dbK6FQDL9znJztpfT-2B69TM65I2pDWGvrQu5Q-2BzjrPfhSSRQ22lKYLEX=
Qt3xByvOaGA-3D Last accessed: December 2023.
4. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with ps=
oriatic arthritis, na=C3=AFve to biologic treatment: a randomised, double-b=
lind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(1037=
0):25=E2=80=9337.
5. Merola JF, Landew=C3=A9 R, McInnes IB, et al. Bimekizumab in patients wi=
th active psoriatic arthritis and previous inadequate response or intoleran=
ce to tumour necrosis factor-=CE=B1 inhibitors: a randomised, double-blind,=
placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):3=
8=E2=80=9348.
6. van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of=
bimekizumab in axial spondyloarthritis: results of two parallel phase 3 ra=
ndomized controlled trials. Ann Rheum Dis. 2023;82(4):515=E2=80=9326.
7. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Cli=
n North Am. 2015;41(4):545=E2=80=9368.=C2=A0
8. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: The di=
agnosis and pharmacologic treatment of psoriatic arthritis in patients with=
psoriasis. Drugs. 2014;74(4):423=E2=80=9341.
9. Deodhar A. Understanding axial spondyloarthritis: A primer for managed c=
are. Am J Manag Care. 2019;25:S319=E2=80=9330.
10. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthriti=
s in the United States: Estimates from a cross-sectional survey. Arthritis =
Care Res (Hoboken). 2012;64(6):905=E2=80=9310.
11. Hamilton L, Macgregor A, Toms A, et al. The prevalence of axial spondyl=
oarthritis in the UK: a cross-sectional cohort study. BMC Musculoskelet Dis=
ord. 2015;16:392.
12. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of b=
imekizumab, a humanized monoclonal antibody and selective dual inhibitor of=
IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991=
=E2=80=931001.
GenericFile
UCB PR BKZ Japan Dec 27 2023 ENG (https://u7061146.ct.sendgrid.net/ls/click=
?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6elFAkTlNf9IRjfBprWAH-=
2BoSuWgJhLMQiJDXNqasOxi4o8-2BKKpK7rXwGSQMPvzSVVMY-3DlwSl_xDPID0vOuylFAU8fv4=
e60wei4JxqEGBdVWu7KiDwjI08XD0QNwOr-2FIUHus1SulXMZQic-2FUwvA-2BfPsk4gNr-2BW6=
M70OIHMB7vQEQ19ecNE7nFy8buOLD3011XKEBm5XlxgihIWov8LLIWj4b4iR9qSmoqQ1bPTPP-2=
BLiQmRDbGKXNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8rg1Ky8Ugkfp3-2BXtU2WXFaszBXcx9PakH=
OzdzRg3bu2NCK4waAZQrVjbnx2K-2FAiCmijYeo6JwFnERMlrbk0nEXljoMQmxVdIV08RaG356l=
nxX3k8GsaNxch0x0o-2FQvZGOkhKyI9sHf8lrVfWWsofnFDO-2F-2B7zafQlE7fsw-3D
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXscmCT8R0oRY6XcgTlaFCfK5K5w1BnSI=
j67e8-2Bn-2F4su-2FcI6tzEBMN4dQNoxdrM1p4VkIFJ30Tjv0XzBsK1SC5SA9vlpP8nb5e6fUN=
pTk68YU-3DJPnc_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI08XD0QNwOr-2FIUHus=
1SulXMZQic-2FUwvA-2BfPsk4gNr-2BW6M70OIHMB7vQEQ19ecNE7nFy8buOLD3011XKEBm5Xlx=
gihIWov8LLIWj4b4iR9qSmoqQ1bPTPP-2BLiQmRDbGKXNv5dBoNfUDc3Ga8nPN7EBoMOEmsLC8r=
g1Ky8Ugkfp3-2BXoWg1Usi5qQ5JxpbSjYMRNqQAReD7JU4Oo8jfmcEvvMUtney3Un2eSNNZXBgw=
Ok8yyc2mEWSBR4GqMYZ0PNLOe1Kgj8GidVe4PfPznIixCjJ1iuBHazSZrOguN9vL7wvc-2FIJxc=
SXxIF6w9bTXPeIObo-3D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01